Adeno-associated viruses (AAV) have emerged as pivotal delivery vehicles for gene therapy due to their overall safety (less immunogenic), efficiency (broad tropism), and long-term gene expression.

Viral vectors have become increasingly used in biotherapies research and development, and adeno-associated virus (AAV) is now the main vector for gene therapy. Different AAV production platforms can ...

High-throughput virology, design of experiments, and small-molecule production enhancers optimize yield and increase ...

Pharmaron Biologics, Liverpool, UK, is a commercial development and manufacturing organization (CDMO) that offers a range of unique end-to-end laboratory services for the development and manufacture ...

In recent years, AAV manufacturing processes have evolved significantly to not only address the need for later-stage clinical and commercial supplies, but also to address regulatory concerns around ...

SOUTH SAN FRANCISCO, Calif., May 03, 2023 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially ...

Efficient production of Adeno-Associated Virus (AAV) vectors at scale for in vivo gene therapies remains a key bottleneck for broad patient access and sustainable manufacturing costs. Virica and ...

COLUMBUS, Ohio, March 25, 2024 /PRNewswire/ -- Andelyn Biosciences, Inc., a pioneering and patient-focused cell and gene therapy Contract Development and Manufacturing Organization (CDMO), has ...

Leveraging Northway Biotech’s 20+ years of CDMO expertise, Diorasis Therapeutics is advancing AAV gene therapy for glaucoma treatment VILNIUS, LT / ACCESS Newswire / July 29, 2025 / Diorasis ...